brickell
biotech
announces
approval
sofpironium
bromide
gel
japan
treatment
primary
axillary
hyperhidrosis
received
development
partner
kaken
pharmaceutical
japan
first
country
approve
sofpironium
bromide
commercial
launch
expected
later
year
brickell
track
initiate
pivotal
phase
program
sofpironium
bromide
boulder
globe
newswire
brickell
biotech
brickell
nasdaq
bbi
pharmaceutical
company
focused
developing
innovative
differentiated
prescription
therapeutics
treatment
debilitating
skin
diseases
announced
today
japanese
development
partner
kaken
pharmaceutical
kaken
received
approval
manufacture
market
sofpironium
bromide
gel
brand
name
japan
treatment
primary
axillary
underarm
hyperhidrosis
thrilled
japanese
approval
sofpironium
bromide
first
topical
prescription
product
approved
japan
treatment
primary
axillary
hyperhidrosis
commented
robert
brown
chief
executive
officer
brickell
significant
milestone
brickell
kaken
kaken
focus
efforts
commercial
launch
sofpironium
bromide
gel
japan
expected
occur
later
year
importantly
novel
therapy
soon
available
help
improve
quality
life
japanese
patients
suffering
debilitating
regulatory
approval
based
results
japanese
phase
pivotal
registration
study
sofpironium
bromide
gel
patients
primary
axillary
hyperhidrosis
primary
secondary
efficacy
endpoints
demonstrated
statistically
significant
differences
sofpironium
bromide
gel
vehicle
placebo
addition
sofpironium
bromide
gel
deemed
safe
generally
well
tolerated
study
well
accompanying
safety
extension
study
japan
sublicense
agreement
kaken
brickell
entitled
receive
milestone
payments
well
tiered
royalties
based
percentage
net
sales
sofpironium
bromide
gel
japan
importantly
kaken
rights
develop
commercialize
sofpironium
bromide
korea
china
certain
asian
countries
turn
attention
markets
sofpironium
bromide
currently
developed
brickell
treatment
primary
axillary
hyperhidrosis
brickell
track
initiate
pivotal
phase
program
sofpironium
bromide
gel
fourth
quarter
ultimately
comprised
two
pivotal
phase
trials
evaluate
sofpironium
bromide
gel
compared
vehicle
approximately
subjects
per
trial
primary
axillary
hyperhidrosis
sofpironium
bromide
sofpironium
bromide
proprietary
new
chemical
entity
belongs
class
medications
called
anticholinergics
anticholinergics
block
action
acetylcholine
chemical
transmits
signals
within
nervous
system
responsible
range
bodily
functions
including
activation
sweat
glands
sofpironium
bromide
retrometabolically
designed
retrometabolic
drugs
designed
exert
action
topically
potentially
rapidly
metabolized
less
active
metabolite
absorbed
blood
proposed
mechanism
action
may
allow
highly
effective
doses
used
limiting
systemic
side
effects
sofpironium
bromide
discovered
bodor
laboratories
nicholas
bodor
multi
hof
graduate
research
professor
emeritus
university
florida
sofpironium
bromide
approved
use
country
time
hyperhidrosis
hyperhidrosis
medical
condition
person
sweats
body
requires
regulate
temperature
million
people
population
united
states
population
japan
believed
suffer
primary
axillary
underarm
hyperhidrosis
targeted
first
indication
sofpironium
bromide
common
site
occurrence
hyperhidrosis
affecting
estimated
patients
hyperhidrosis
united
states
million
individuals
estimated
patients
hyperhidrosis
additional
information
found
international
hyperhidrosis
society
website
https
brickell
brickell
biotech
pharmaceutical
company
focused
developing
innovative
differentiated
prescription
therapeutics
treatment
debilitating
skin
diseases
brickell
pipeline
consists
potential
novel
therapeutics
hyperhidrosis
prevalent
dermatological
conditions
brickell
executive
management
team
board
directors
bring
extensive
experience
product
development
global
commercialization
served
leadership
roles
large
global
pharmaceutical
companies
biotechs
developed
launched
successful
products
including
several
achieved
iconic
status
brickell
strategy
leverage
experience
acquire
develop
commercialize
innovative
products
brickell
believes
successful
currently
underserved
dermatology
global
marketplace
information
visit
http
cautionary
note
regarding
statements
statements
made
press
release
relating
future
financial
legal
business
research
clinical
performance
conditions
plans
prospects
trends
strategies
matters
including
without
limitation
anticipated
timing
scope
design
results
future
clinical
trials
intellectual
property
rights
including
validity
term
enforceability
expected
timing
results
regulatory
approvals
prospects
commercializing
brickell
product
candidates
research
collaborations
partners
including
japan
united
states
country
statements
within
meaning
private
securities
litigation
reform
act
addition
used
press
release
words
may
could
anticipate
believe
estimate
expect
intend
plan
predict
similar
expressions
variants
relate
brickell
may
identify
statements
brickell
cautions
statements
subject
numerous
assumptions
risks
uncertainties
change
time
often
quickly
unanticipated
ways
important
factors
may
cause
actual
results
differ
materially
results
discussed
statements
historical
experience
include
risks
uncertainties
including
without
limitation
ability
obtain
adequate
financing
advance
product
development
ability
maintain
enforce
intellectual
property
rights
potential
delays
reason
product
development
regulatory
changes
unsuccessful
clinical
trials
unanticipated
demands
cash
resources
disruption
business
caused
current
pandemic
interruptions
disruption
inability
launch
commercialize
product
kaken
japan
obtain
adequate
pricing
approval
risks
associated
developing
obtaining
regulatory
approval
commercializing
product
candidates
information
factors
risks
could
cause
actual
results
differ
statements
contained
brickell
filings
united
states
securities
exchange
commission
sec
available
http
http
statements
represent
estimates
brickell
date
hereof
brickell
specifically
disclaims
duty
obligation
update
statements
et
al
hyperhidrosis
update
prevalence
severity
united
states
arch
dermatol
res
fujimoto
et
al
epidemiological
study
considerations
focal
hyperhidrosis
japan
j
dermatol
brickell
investor
contact
dan
ferry
lifesci
advisors
daniel
